Document
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-24T09:28:47
publisher: Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
type: Document
label: RDF description of Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial - http://irises.unisr.it/resource/item/97234

5359547
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

Generically Dependent Continuant
type: Class

Article
type: Class

Inglese
type: Language

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
language: Inglese
type: Continuant
type: Document
type: Academic Article
type: Thing
related by: 5359547
type: Article
type: Information Content Entity
most specific type: Academic Article
type: Generically Dependent Continuant
type: Entity

Information Content Entity
type: Class